Добавил:

Sekretar kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.

Вуз:

Ростовский Государственный Медицинский Университет

Предмет:

Медицина общая

Файл:

Книга_3773_Библиотеки_им_академика_М_И_Перельмана

.pdf

Скачиваний:

Добавлен:

02.09.2026

Размер:

20 Мб

Скачать

☆

<<< < Предыдущая 20 21 22 23 24 25 26 27 28 29 30 31 3233 / 4433 34 35 36 37 38 39 40 41 42 43 44 > Следующая >>>

318

Follow-up

(months) Instrument(s)

No of patients

in Ablation arm

reporting QoL

data

Total

no. of

patients

360 360 12 BDI; HADS;

K. L. Withers et al.

SF-36; STAI

61 61 12 SF-36

other relevant demographics

(race, employment, obesity,

diabetes, physical activity,

Table 16.1 (continued)

smoking, alcohol, no leisure

physical activity)

APPROVAL Study- A

prospective, randomised,

single blind multicentre

study with centres in Italy

and the USA.Consecutive

patients enrolled between

Jan 2009 and Sept 2011.

sex=female

n (%)

NR (22)

group 1a

NR (28)

group 1b

NR (24)

group 2

63±8 group 1 a

61±11 group 1 b

62±9 group 2

To examine the impact of

different ablation

strategies on atrial

brillation (AF)

recurrence and quality of

life in coexistent AF and

atrial utter (AFL)

Paper Study intent age

Mohanty

etal. [63]

360 enrolled patients with

documented coexistent AF

and AFL were blinded and

randomized to 2 groups:

Group 1 (182 patients)

where 58 patients had

AF+AFL ablation (group

1a) and 124 had AF

ablation only Group 1b).

Group 2 (178 patients):

only AFL was ablated by

achieving bidirectional

isthmus conduction block.

QoL data presented for

total of Group 1 and

Group 2

62±13 NR (29) Prospective single centre,

To report impact of

Mohanty

single arm centre.

Consecutive patients

undergoing rst catheter

ablation or asymptomatic

LSP-AF. 25 patients

experienced recurrence,

21 of these were

catheter ablation on

exercise performance,

QoL and symptom

perception in

asymptomatic

longstanding persistent

AF (LSP-AF)

etal.[64]

symptomatic

16 QOL andPROMS inCatheter Ablation ofCardiac Arrhythmia

Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/

SSQ

319

(continued)

127 66 24 EQ5D

RCT of 127 treatment

naïve patients with

paroxysmal AF treated at

16 centres in Europe and

North America, enrolled

between July 2006 and

Jan 2010. 66 patients

15 (22.7)

ablation

group

16 (26.2)

AAD group

56.3 (9.3) ablation

group

54.3 (11.7) AAD

group

139 139 12 EQ5D-5L;

treated with ablation; 61

treated with anti-

arrhythmia drugs

Prospective single centre

randomised study of

patients with symptomatic

AF. 69 patients treated

with single cryoablation;

21 (30.04)

single cryo

16 (22.9)

routine

61.9±9.08 single

cryo

68.3±10.0 routine

70 with routine

cryoablation. Patients

enrolled between Nov

2014 and March 2016

1040 432 12 AFEQT

multicentre outpatient-

based AF Japanese

registry. Patients with

persistent AF divided into

four groups; those who

underwent catheter

NR NR An observational and

ablation and maintained

sinus rhythm; patients

who underwent catheter

ablation and had

non-sinus rhythm at the

1year follow-up; patients

who maintained sinus

rhythm by AAs; and

patients who did not

undergo catheter ablation

or AA treatment

To compare

radiofrequency ablation

with antiarrhythmic drugs

in treating patients with

paroxysmal AF as a

Morillo etal.

[65]

rst-line therapy

Single cryoballoon (CB)

application per vein for

pulmonary vein isolation

(PVI) compared to the

standard approach of two

consecutive CB

applications in patients

with atrial brillation

Mortsell etal.

[66]

(AF) for long-term

efcacy and safety

To understand whether

use of catheter ablation

would lead to better QOL

in comparison to

Nakajima

[67]

antiarrhythmic drugs

320

Follow-up

(months) Instrument(s)

No of patients

in Ablation arm

reporting QoL

data

Total

no. of

patients

79 79 12 AFQLQ

259 45 12 AFQLQ

State-Trait

70 70 3 SF36;

Anxiety

Inventory

(STAI)

K. L. Withers et al.

218 107 12 AFEQT: SF-36

other relevant demographics

(race, employment, obesity,

diabetes, physical activity,

Table 16.1 (continued)

smoking, alcohol, no leisure

physical activity)

patients with

asymptomatic persistent

AF treated at Tenri

hospital. Unclear if any

cross over with Onishi et

al. [69]

sex=female

n (%)

NR NR Retrospective analysis of

To examine the effect of

CA for asymptomatic AF

patients

Paper Study intent age

Onishi etal.

[68]

A retrospective single-

centre study with patients

undergoing an initial RF

ablation CA of AF in

Tenri Hospital (Japan)

from January 2012 to

March 2014.

62.9±8.6 5 (11.1)

To assess the

improvement of QOL and

long-term prognosis after

CA of asymptomatic

persistent AF

Onishi etal.

[69]

49.31±15.29 50 (71) Consecutive patients with

To investigate effects of

Papiashvili

AVNRT/AVRT or Atrial

Tachycardia, enrolled

between July 2016 and

April 2017 and

prospectively followed up.

Results compared by

gender, age and SVT type

catheter ablation on

HRQoL related to age,

gender and type pf

paroxysmal

supraventricular

tachycardia

etal. [70]

A multicentre (Europe,

Argentina and Australia),

prospective, open

blind-endpoint, controlled

randomized (1:1) study

evaluating PVI using CBA

vs AAD therapy in

patients with symptomatic

Ablation

group=31

(29)

AAD

group=39

(35.1)

Ablation

(n=107)=50.5

(13.1)

AAD

(n=111)=54.1

(13.4)

To present the impact of

pulmonary vein isolation

(PVI) using CBA

compared to AAD

therapy on symptom

recurrence and QoL

Pavlovic etal.

[71]

paroxysmal AF

16 QOL andPROMS inCatheter Ablation ofCardiac Arrhythmia

Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/

321

(continued)

SF-12

≥12

229 163

patients scheduled for PVI

in Vienna between 2009

and 2013 with a diagnosis

of paroxysmal, persistent

or longstanding AF.SF12

available for 163 patients

regarding 187 PVI

SF12

518 518 3 EQ-5D-5L;

procedures

AXAFA–AFNET 5

enrolled patients

scheduled for a de novo/

rst AF ablation with at

least one established

stroke risk factor

(age>65years, heart

failure, hypertension,

diabetes or prior stroke).

For the purpose of this

analysis, the study

population included all

patients from the AXAFA

trial population who were

44 44 3 SF-36

randomised, underwent

catheter ablation and had

available baseline and

follow-up QoL data.

N.B.Sub group of

Kloosterman etal.

cohort of patients with

symptomatic drug

refractory ventricular

arrhythmia. 23 patients

with VT; 21 with PVCs.

Patients enrolled between

1999 and 2004

58±11 NR (27) A retrospective analysis of

paroxysmal or non-

paroxysmal AF increases

HRQoL

To determine if PVI for

Pezawas etal.

[98]

(33.6%)

Overall=64 (58–70) 174

To investigate changes in

quality of life (QoL),

cognition and functional

status according to

arrhythmia recurrence

after atrial brillation

Piccini etal.

[27]

N.B.Same

study

population as

Kloosterman

(AF) ablation

etal. [26]

45.5±14.2 34 (NR) Single centre prospective

To evaluate the HRQoL

of patients with

structurally normal hearts

undergoing elective RF

ablation (RFA) of

ventricular tachycardia

(VT) or premature

Pytkowski

etal. [72]

ventricular contractions

(PVC’s).

322

Follow-up

(months) Instrument(s)

No of patients

in Ablation arm

reporting QoL

data

Total

no. of

patients

80 80 3 AFEQT; SF-36

Symptom

checklist

159 103 3 SF-36; AF

HADS; SF-36

24 AFEQT;

cardiac

rehabilitation

group; 105in

210 210 (105in

usual care

group)

K. L. Withers et al.

EQ-5D-3L

12 AFEQT;

115 CRYO-2

115 CRYO-4

346 115 CF-RF

other relevant demographics

(race, employment, obesity,

diabetes, physical activity,

Table 16.1 (continued)

smoking, alcohol, no leisure

physical activity)

scheduled for their rst

ablation, with prospective

follow up: 44 patients

with Paroxysmal AF; 36

patients with persistent

sex=female

n (%)

57±10years 22 (27) Consecutive patients

To assess the effect of

catheter ablation on AF

symptoms and QoL

Paper Study intent age

Raine etal.

[73]

A prospective, randomised

multicentre trial for

patients with paroxysmal

AF not controlled by

drugs. 103 patients in

ablation group; 56 patients

32 (31)

ablation

group;

21 (37)

AAD group

55.5±9.4 ablation

group

55.8±13.1 AAD

group

To assess effects of

catheter ablation and

antiarrhythmic drugs

(AAD) on QoL in

patients with paroxysmal

Reynolds

etal. [74]

in AAD group

2 Danish university

hospitals treated with

ablation for AF were

screened. Patients were

randomized 1:1 to

59 26% Consecutive patients from

To assess outcomes at 12

and 24months after

participation in a

multidisciplinary cardiac

rehabilitation program

plus usual care compared

Risom etal.

[75]

comprehensive cardiac

rehabilitation plus usual

care vs usual care

stratied by age and type

of AF

the CIRCA-DOSE study

([28]; [30]). Patients

60(52-66 IQR) 115 (33.3) A secondary analysis of

with usual care alone for

patients treated for atrial

brillation with catheter

ablation

To determine the

association between

change in AF burden and

Samuel etal.

[29]

N.B.Same

enrolled between Sept

2014 and July 2017

quality of life in the year

following ablation

study

population as

Andrade etal.

[28], Yao

etal. [30]

16 QOL andPROMS inCatheter Ablation ofCardiac Arrhythmia

Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/

Anxiety Scale

(SAS);

Self-Rating

Depression

Scale (SDS);

SF-36. No

disaggregated

follow-up data

available for

SDS or SAS

scales

SF-36; AF

Severity Scale;

EQ-5D;

Symptom

Checklist

323

(continued)

(SCL) Score

166 82 12 Self-Rating

Consecutive patients with

a primary diagnosis of

symptomatic paroxysmal

AF enrolled between Feb

2009 and Jan 2010 for

prospective review. 84

patients included in

27 (32.9) in

ablation

group

26 (30.9) in

AAD group

55.9±6.1in ablation

group

57.2±5.4in AAD

group

95 95 12 SF-36

antiarrhythmic drug

(AAD) group; 82 patients

in ablation group

patients with Atrial Flutter

64±11 18 (18.9) Consecutive Spanish

219 76 3 AFEQT;

referred between Jan 2003

and March 2005, with

prospective follow up

study of patients with

paroxysmal, persistent,

62.1±12 91 (42.5) A multicentre prospective

longstanding persistent or

permanent AF recruited in

Canada and the US between

Aug 2008 and July 2009.

Three groups in study.

Before and after treatment

QoL presented here for two

groups: Group 1—

pharmacological change in

therapy following baseline

assessment (n=66; mean

age 66; 32 females); Group

2—ablation after baseline

assessment (n=76; mean

age 60.1; 27 females)

To assess if depression,

anxiety, and QoL improve

after catheter ablation in

patients with paroxysmal

Sang etal.

[76]

To measure HRQoL

changes in patients with

typical atrial utter

following catheter

ablation with results

standardised and

normalised to the Spanish

Seara etal.

[77]

population

To develop and validate

the AFEQT in patients

with AF in a 6 centre

Spertus etal.

[78]

prospective study

324

Follow-up

(months) Instrument(s)

No of patients

in Ablation arm

reporting QoL

data

Total

no. of

patients

2008 636 12 AFEQT

165 165 12 AFEQT; SF-12

K. L. Withers et al.

SF-36

549 549 18 EQ-5D-3L;

other relevant demographics

(race, employment, obesity,

diabetes, physical activity,

Table 16.1 (continued)

smoking, alcohol, no leisure

physical activity)

The ORBIT-AF registry is

a national, US prospective

cohort study of outpatients

with AF, enrolled from

June 2010 to August 2011.

The study was managed

and coordinated by the

sex=female

n (%)

(47.2%)

74.0 (67.0–81.0) 300

To identify patients who

experience large

improvements in HRQoL;

to understand patient

factors associated with

large improvements in

HRQoL; and to describe

Paper Study intent age

Steinberg

etal. [79]

Duke Clinical Research

Institute

interval interventions and

outcomes among these

patients with large

refractory symptomatic

PsAF were enrolled into

65±9 49 (29.7) Patients with drug

improvements in HRQoL

efcacy of PVI using the

cryoballoon catheter to

Su etal. [80] To assess the safety and

the STOP Persistent AF

trial (US, Canada and

Japan) between March

2017 and July 2018. 165

patients were treated by

cryoballoon PVI, and 145

treat patients with

persistent AF

completed the required

12-month follow up

follow-up schedule

STAR AF II RCT, patients

enrolled at 35 centres in

Europe, Canada,

Australia, China, and

60 (SD 9) 115 (21) Secondary analysis of the

To evaluate whether the

procedural outcome of

ablation for AF is

associated with quality of

life (QOL) measures

Terricabras

etal. [81]

Korea from November

2010 to July 2012

16 QOL andPROMS inCatheter Ablation ofCardiac Arrhythmia

Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/

EQ5D-3L;

SF-36

ASTA

325

(continued)

EQ-5D-5L

37 37 12 SF-36; MASQ

study enrolling patients

with ventricular

extrasystoles between

2016 and 2019

49±22 26 (70.3) Single centre Belgian

176 156 12 EQ-5D-3L;

consecutive patients with

AVNRT or PSVT treated

at a single centre in

48.3±16.3 91 (52) Prospective design with

294 146 24 SF-36;

A Swedish multicentre

prospective RCT

Sweden. Age and gender

matched to Swedish

population

including patients with

46 (32)

RFA group

42 (28)

56±9 RFA group;

54±10 AAD group

PAF. 146 patients treated

with RFA; 148 treated

with AAD.

AAD group

203 104 12 AFEQT;

Part of the STOP-AF

Study. Patients with

symptomatic AF not

previously receiving

rhythm control therapy

41 (39.4)

Ablation

group

42 (42.4)

AAS group

60.4±11.2

(Ablation group)

61.6±11.2 (AAD

group)

were randomized to AAD

(class I or III) or CBA

study of the MANTRA-

PAF) trial, and symptom

burden at 12 and

Evaluation of the impact

of catheter ablation for

ventricular extrasystoles

(VES) in structurally

normal hearts on quality

of life (QOL) and

symptomatology

Timmers

etal. [82]

To evaluate the impact of

RFA on HRQOL in

patients with paroxysmal

supraventricular

tachycardia (PSVT)

Walfridsson

etal. [83]

To assess long-term effect

on HRQoL of

radiofrequency ablation

(RFA) vs. antiarrhythmic

Walfridsson

etal. [96]

drug therapy (AAD) as

rst-line treatment for

patients with PAF (sub

24months

To evaluate the change in

quality of life (QoL) and

symptoms after rst-line

CBA vs AAD therapy

Wazni etal.

[84]

326

AF Symptom

Follow-up

(months) Instrument(s)

No of patients

in Ablation arm

reporting QoL

data

Total

no. of

patients

167 106 9 (QoL data

Checklist;

SF-36

reported only

at 3months)

502 323 24 SF-36

K. L. Withers et al.

33 33 12 SF-36

other relevant demographics

(race, employment, obesity,

diabetes, physical activity,

Table 16.1 (continued)

smoking, alcohol, no leisure

physical activity)

randomised study with

sites in the USA, Europe,

Canada and Latin America

involving patients with

symptomatic AF who had

not improved with at least

sex=female

n (%)

NR(33.5) Prospective multicentre

55.7 (95% CI,

54.1-57.4)

To determine the efcacy

of catheter ablation

compared with

antiarrhythmic drug

therapy (ADT) in treating

symptomatic paroxysmal

Paper Study intent age

Wilber etal.

[85]

1 drug. 167 patients with

paroxysmal AF:106

patients treated with

catheter ablation; 61

treated with

AAD.Patients enrolled

between Oct 2004 and Oct

2007

symptomatic AF treated at

a single US centre.

Patients prospectively

followed between Dec

55.9±0.3 98 (18) Consecutive patients with

To determine the

relationship between AF

ablation efcacy, QoL,

and AF-specic

symptoms at 2years

Wokhlu etal.

[86]

available for patients with

2001 and July 2006 and

data collected

prospectively until March

2008.323 patients with

2year QoL follow up

and without recurrence of

54.2±9 7 (21) Prospective study. Data

To assess the long-term

inuence of

circumferential

Wozniak-

Skowerska

etal. [87]

pulmonary vein ablation

(CPVA) on QoL in

patients with AF

16 QOL andPROMS inCatheter Ablation ofCardiac Arrhythmia

Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/

327

(continued)

648 327 60 SF-36

From 2012 to 2014, 648

patients with persistent

AF (PAF) or longstanding

persistent AF LS-PAF)

were enrolled in a

multicentre RCT. 267

(41.2%) patients had PAF

and 381 (58.8%) had

109 (33.3)

Ablation

group

118 (36.8)

Pharmaco-

therapy

group

64.1±11.3 Overall

64.8±12.6 Ablation

group

64.4±13.6

Pharmacotherapy

group

130 122 12 AFEQT; SF-36

LS-PAF

UK based RCT of patients

with persistent AF or

sustained paroxysmal AF

with risk  for

atrial substrate. 64

61.9±0.5 42 (32) Prospective multicentre

123 66 6 SF-36

patients treated with PVI

only; 66 with PVI and

additional linear ablation

lines

Prospectively enrolled

patients with AF: 66

patients treated with

CPVI; 57 treated with

CPVI=21;

ADT =22

61.5±10.1 CPVI

group: 60.9±13.7

ADT group

ADT

34 34 6 SF-36

patients with

asymptomatic persistent

AF, prospective follow up

60.4±9.2 7 (21) Consecutively enrolled

RFCA and

pharmacotherapy on the

prognosis of patients with

persistent and long

standing AF

Wu etal. [88] To compare the effects of

To assess the impact of

additional linear ablation

lines compared to PVI

alone

Wynn etal.

[89]

circumferential pulmonary

vein isolation (CPVI)

compared with

antiarrhythmic drug therapy

(ADT) in treating AF.

To assess the QoL,

exercise performance,

and plasma B-type

natriuretic peptide levels

following catheter

ablation in patients with

asymptomatic AF.

Xu etal. [90] To evaluate QoL after

Yagishita

etal. [91]

<<< < Предыдущая 20 21 22 23 24 25 26 27 28 29 30 31 3233 / 4433 34 35 36 37 38 39 40 41 42 43 44 > Следующая >>>

Соседние файлы в папке Библиотека им академика М.И. Перельмана

#
02.09.202621 Мб0Книга_3768_Библиотеки_им_академика_М_И_Перельмана.pdf
#
02.09.202621 Мб0Книга_3769_Библиотеки_им_академика_М_И_Перельмана.pdf
#
02.09.202621 Мб0Книга_3770_Библиотеки_им_академика_М_И_Перельмана.pdf
#
02.09.202621 Мб0Книга_3771_Библиотеки_им_академика_М_И_Перельмана.pdf
#
02.09.202620 Мб0Книга_3772_Библиотеки_им_академика_М_И_Перельмана.pdf
#
02.09.202620 Мб0Книга_3773_Библиотеки_им_академика_М_И_Перельмана.pdf
#
02.09.202620 Мб0Книга_3774_Библиотеки_им_академика_М_И_Перельмана.pdf
#
02.09.202620 Мб0Книга_3775_Библиотеки_им_академика_М_И_Перельмана.pdf
#
02.09.202620 Мб0Книга_3776_Библиотеки_им_академика_М_И_Перельмана.pdf
#
02.09.202619 Мб0Книга_3777_Библиотеки_им_академика_М_И_Перельмана.pdf
#
02.09.202619 Мб0Книга_3778_Библиотеки_им_академика_М_И_Перельмана.pdf